Becker’s Muscular Dystrophy Treatment Market Expected to Grow by 2030 | Key companies – PTC Therapeutics, Italfarmaco, Epirium Bio, Edgewise Therapeutics and many others

“Delveinsight LLP Commercial Research”

DelveInsight’s “Becker Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast 2030” report provides an in-depth understanding of the historical and predicted epidemiology as well as the size and market share of Becker Muscular Dystrophy in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

The Becker Muscular Dystrophy Market Report covers emerging drugs, current treatment practices, individual therapy market share, current and forecast market size from 2017 to 2030.

It assesses current treatment practice / algorithm, market drivers, market barriers and unmet medical needs to organize the best opportunities and assess the underlying potential of the market.

Becker Muscular Dystrophy Market

Becker’s muscular dystrophy: an overview

Becker’s muscular dystrophy (BMD) is an inherited disorder of muscle structure that causes progressive deterioration of the limbs, heart muscles and skeletal muscles. However, the involuntary muscles are not affected. BMD is a milder version of Duchenne muscular dystrophy (DMD). DMD usually begins in adolescence or early adulthood, and the course is slower and much less predictable than that of DMD.

Highlights of the Becker Muscular Dystrophy Market

  • According to the American Association of Neuromuscular and Electrodiagnostic Medicine, about three in 100,000 people have BMD. In addition, few patients with BMD can live a normal lifespan, however, most die after the age of 40.

  • Through several studies, it can be estimated that the occurrence of BMD varies from one in 18,000 to one in 31,000 male births.
  • According to the Information Center for Genetic and Rare Disorders, the prevalence of BMD is estimated between 17 and 27 cases per million people. This means that at any given time, about one in 37,000 to one in 59,000 people are living with BMD.

  • According to the CDC, the estimated prevalence of Duchenne and Becker’s muscular dystrophy (DBMD) was one in 7,250 men aged 5 to 24 years. However, the prevalence of DMD was found to be three times higher than the prevalence of BMD.

Get FREE Sample in Becker’s Muscular Dystrophy Therapeutic Market

Key Benefits of Becker’s Muscular Dystrophy Market Report

  • The report provides an in-depth analysis of Becker Muscular Dystrophy Market Size and Share until 2030 in the seven main markets.

  • The report will help develop business strategies by understanding Becker Muscular Dystrophy market trends, key players, and ongoing developments that are shaping and driving the market growth in the coming years.

  • This covers Current Treatment Practices for Becker’s Muscular Dystrophy, emerging drugs, market share of individual therapies in 7MM.

  • The report provides a detailed assessment of the Becker Muscular Dystrophy market in terms of market drivers and barriers, unmet needs, market opportunities, patient population, detailed pipeline product benchmarking including clinical stage products. and not clinical, and other factors.

Becker Muscular Dystrophy Market

The market outlook section of the report helps to understand in detail the historical, current and forecast Becker Muscular Dystrophy Market Size and Share by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and the demand for better technology.

The report details the Becker Muscular Dystrophy Market Trend for each drug marketed and therapies in the terminal phase by evaluating their impact according to the annual cost of the treatment, inclusion and exclusion criteria, the mechanism of action, the increase in the number of patients, the patient segment coverage, planned launch year, competition with other therapies, brand value, their impact on the market and the views of key opinion leaders.

Epidemiology of Becker’s muscular dystrophy

Epidemiology section covers overviews on history and current affairs Becker muscular dystrophy patient pool and predicted trends for seven major countries from 2017 to 2030. It helps recognize the causes of current and projected trends by exploring numerous studies and perspectives from key opinion leaders. The epidemiology section also provides the pool of patients diagnosed and their trends as well as the hypotheses adopted.

Epidemiological segmentation of Becker’s muscular dystrophy (BMD)

Becker Muscular Dystrophy Drug Adoption and Pipeline Development Activities

The section on drug absorption focuses on the rate of absorption of potential drugs recently launched in the Becker Muscular Dystrophy Market or is expected to be marketed during the study period. The analysis covers the drug uptake of Becker muscular dystrophy market; absorption of patients by therapies; and the sales of each drug.

The drug absorption section of the report helps to understand the drugs with the fastest absorption, the reasons for the maximum use of new drugs, and helps to compare drugs on the basis of market share and size. size, which will again be useful for studying the important factors in market absorption. and in financial and regulatory decision making.

The report also covers Becker Muscular Dystrophy Development Activities and provides valuable information on various phase II and phase III therapeutic candidates and on key market companies involved in the development of targeted therapies. It also analyzes recent developments such as collaborations, acquisitions and mergers, license patent details and other information on emerging therapies.

Treatment for Becker’s muscular dystrophy focuses on reducing the symptoms associated with it. There is no cure, but treatments are available to relieve symptoms and maximize muscle function. It is essential that a person with BMD stays in good shape and continues to use their muscles.

To close the gap in the treatment landscape, several companies around the world are actively working to develop therapies for Becker’s muscular dystrophy (BMD).

The Major Players in the Becker Muscular Dystrophy (BMD) Market are:

  • Therapeutic PTC

  • Italfarmaco

  • Epirium Bio

  • Edgewise Therapeutics

And others

Becker’s muscular dystrophy (BMD) therapies covered in the report include:

  • Translarna

  • Givinostat

  • EPM-01

  • GED-5506

And many more.

According to DelveInsight, the dynamics of Becker Muscular Dystrophy (BMD) Market is expected to change in the coming years due to the positive results of the pipeline’s emerging candidates during the development phase by major players. The launch of emerging therapies is expected during the forecast period 2021-2030.

Sample Request @ Becker Muscular Dystrophy Emerging Therapies and Key Companies

Contents

1. Key information

2. Executive summary

3. Competitive intelligence analysis of Becker’s muscular dystrophy

4. Becker Muscular Dystrophy Market Overview at a Glance

5. Background and overview of Becker’s muscular dystrophy disease

6. Pathway of the patient with Becker’s muscular dystrophy

7. Becker’s Muscular Dystrophy Epidemiology and Patient Population

8. Becker’s muscular dystrophy treatment algorithm, current treatment and medical practices

9. Unmet Needs in Becker’s Muscular Dystrophy

10. Main endpoints for treatment of Becker’s muscular dystrophy

11. Products marketed against Becker’s muscular dystrophy

12. Emerging therapies for Becker’s muscular dystrophy

13. Major Market Analysis of Becker Seven Muscular Dystrophy

14. Attribute analysis

15. Becker Muscular Dystrophy Market Outlook (Top 7 Markets)

16. Overview of access and reimbursement for Becker’s muscular dystrophy

17. KOL’s Opinions on the Becker Muscular Dystrophy Market.

18. Becker’s Muscular Dystrophy Market Drivers

19. Barriers to the Becker Muscular Dystrophy Market

20. Annex

21. Capabilities of DelveInsight

22. Disclaimer

* The table of contents is not exhaustive; final content may vary.

Get FREE sample at: https://www.delveinsight.com/sample-request/becker-muscular-dystrophy-market

Key companies and emerging gene therapy in dermatology

Globally, several leading pharmaceutical companies are exploring the potential application of gene therapy in dermatology, including Krystal Biotech, Castle Creek Biosciences, Biosciences, Almirall, Abeona Therapeutics, Fibrocell Science, Amryt Pharma plc, Sterna Biologicals GmbH & Co. KG, Temprian Therapeutics, Holostem Terapie Avanzate, Azitra, Novartis, AVITA Medical and others. In view of the market outlook and positive results, new players are also expected to enter the field in the coming years which will make it one of the most competitive gene therapy segments. Read more: Leading Dermatology Gene Therapy Companies

About DelveInsight

DelveInsight is a leading business consultant and market research firm focused exclusively on the life sciences. It supports pharmaceutical companies by providing them with complete end-to-end solutions to improve their performance.

Media contact
Company Name: DelveInsight Business Research LLP
Contact: Shruti Thakur
E-mail: Send an email
Telephone: 09650213330
Address:304, boulevard S. Jones # 2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Source link

About Chris Y. Camp

Check Also

Mother / daughter nurse practitioners guide children through cancer treatment, survival

Choose a topic Empower / Inspire October 29, 2021 3 minutes to read Source / …

Leave a Reply

Your email address will not be published. Required fields are marked *